As in previous years, we continued to make significant progress across multiple business areas, advancing our strategic initiative to establish ourselves as the reference partner in the in vitro diagnostics sector for immunoassay and biomaterials development and supply. 

Thanks to our increased credibility and reputation for reliability in the market as a biomaterials developer and manufacturer, in 2024, we started developing two chemiluminescent assays for a top five IVD company. We also expanded the commercialization of our first pre-market approval product for another leading IVD company, manufacturing the first lot to stock for the Chinese market and preparing the IVDR regulation product launch. 

We developed 13 new biomaterials and completed the manufacturing transfer and validation of five products. During the year, we also worked to ensure our core business supply chain, designing a plan to develop several key raw materials for our Transfusion business unit. 

We also strengthened our commitment to quality and operational excellence through impactful initiatives. We conducted over 700 training sessions covering specific quality topics and Quality & Regulatory procedures and implemented 300 continuous improvement initiatives. During the Quality Week, Chartered Quality Institute and International Register of Certificated Auditors initiative, we expanded our efforts by organizing quality-focused activities and passed multiple external audits, achieving recertification for ISO 13485, Medical Device Single Audit Program, and IVD regulation.